Fcγ Receptors on Mast Cells: Activatory and Inhibitory Regulation of Mediator ReleaseTkaczyk C.a · Okayama Y.b · Metcalfe D.D.a · Gilfillan A.M.a
aLaboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md., USA; bLaboratory of Allergy Transcriptome, Research Center for Allergy and Immunology, RIKENYokohama Institute, Yokohama, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Mast cell activation and subsequent release of proinflammatory mediators are primarily a consequence of aggregation of the high affinity receptors for IgE (FcΕRI) on the mast cell surface following antigen-dependent ligation of FcΕRI-bound IgE. However, data obtained from rodent and human mast cells have revealed that IgG receptors (FcγR) can both promote and inhibit mast cell activation. These responses appear to be species and/or mast cell phenotype dependent. In CD34+-derived human mast cells exposed to interferon-γ, FcγRI is upregulated, FcγRII is expressed but not upregulated, and FcγRIII is not expressed. In contrast, in mouse mast cells, FcγRII and FcγRIII receptors are expressed, whereas FcγRI is not. Aggregation of FcγRI on human mast cells promotes mediator release in a manner generally similar to that observed following FcΕRI aggregation. Aggregation of FcγRIIb in mouse mast cells fails to influence cellular processes; however, when coligated with FcΕRI, signaling events thus activated downregulate antigen-dependent mediator release. These divergent responses are a consequence of different motifs contained within the cytosolic tails of the signaling subunits of these receptors and the specific signaling molecules recruited by these receptors following ligation. The studies described imply that data obtained in rodent models regarding the influence of FcγRs on mast cells may not be directly translatable to the human. The exploitation of FcγRs for a potential therapy for the treatment of allergic disorders is discussed in this context.
© 2004 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.